Public Health
publicado em 07/07/2014 às 12h39:00
   Dê o seu voto:

Drug combination reduced side effects in the treatment of leukemia

Zebularina chemotherapy and methotrexate are effective in smaller doses than when administered separately

 
font size
A-
A+

Some pieces of information on this page may have been automatically translated. Makernews is not responsible for the irregularities resulting from these translations. When in doubt,      consult the original text.



Foto: Marcos Santos/USP Imagens
Search Zebularina tested alone and in combination with two other drugs.
  « Previous
next »  
Search Zebularina tested alone and in combination with two other drugs.

Research at the University of São Paulo (USP) in Ribeirão Preto shows that the use of the drug Zebularina is effective in the treatment of Acute Lymphoblastic Leukemia (ALL) pediatric, especially in a joint application with the chemotherapeutic agent methotrexate (MTX). The results show that, if administered together, the two drugs are effective in smaller doses than if administered separately. The need fewer drugs in cancer therapy decreases the incidence of side effects.

According to the author of the study, biologist Augusto Andrade Faria, this drug is not used in any treatment, but in other in vitro studies [which occurs in artificial medium, without the use of animals] it has been tested in a large variety (of cancer), such as breast, prostate, leukemia, lymphoma, glioblastoma, and always succeeded.

The Acute Lymphoblastic Leukemia is the most common blood cancer in childhood, but also affects adults. About 20% of people who have this disease develop it again. In this disease, the abnormal cells replace, in bone marrow, healthy cells, and production of blood cells is impaired.

Treatment for ALL performed at Hospital das Clinicas (HC) currently occurs according to the Brazilian Group for Treatment of Childhood Leukemia (GBTLI). Involves several steps, such as induction, consolidation of remission, intensification, consolidation and delayed maintenance, and various drugs applied in combination. The duration of treatment in accordance to the researcher, is two to three years, depending on the group.

<b> Next Step </ b>

The drug is not in phase of clinical trials, but Andrade believes that studies of specificity and effectiveness research will help continue to the next stage. To pass the drug to be used in the treatment of leukemia, or even to be tested in humans, said biologist would be more accurate in vitro studies to better understand how the drug which would be metabolized and the possible consequences for human beings. Only then would move to the tests in vivo step, which corresponds to testing in mice, and then human.

The Zebularina have a preference for cancer cells, reducing side effects, the researcher says, noting that it is described as less toxic than similar drugs already approved since 2004, as Azacitidine. Andrade believes that within five or ten years the product can be marketed - factors such as results, funding for studies and approval of the competent bodies as the FDA in the U.S. and ANVISA, Brazil, will influence the process.

With information <i> USP </ i>

Source: Isaude.net
   Palavras-chave:   Leukemia    Zebularina    Methotrexate chemotherapy    Cancer    University of Sao Paulo   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Drug combination reduced side effects in the treatment of leukemia
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Drug combination reduced side effects in the treatment of leukemia


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
leukemia    Zebularina    methotrexate chemotherapy    cancer    University of Sao Paulo   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.